Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

Long-Term Management and Surveillance

At a Glance

Long-term familial hyperaldosteronism type I care combines steroid and blood pressure treatment with home readings, routine electrolyte and kidney tests, and checks for heart, eye, brain, growth, and bone complications. A written sick-day plan is essential during illness or surgery.

Managing Familial Hyperaldosteronism Type I (FH-I) is a long-term journey that focuses on two goals: keeping blood pressure in a safe range and minimizing the side effects of medication [1][2]. Because this condition is so rare, your care team—which should include a specialized endocrinologist—will tailor a surveillance plan specifically for you or your child based on the latest expert consensus [1].

The “Sick Day” Safety Net

If you or your child are taking maintenance glucocorticoids (like dexamethasone or prednisone), your body may become less able to produce its own “stress hormones” when ill or injured [3]. This makes having a “Sick Day” plan essential:

  • Stress Dosing: During times of fever, severe infection, or before surgery, you need a written, individualized plan from your doctor that explicitly instructs how to temporarily increase the dose of medication to help the body handle the stress [4][5]. Never taper or stop glucocorticoids without medical advice.
  • Emergency Injections: If a patient is vomiting and cannot keep their oral medication down, they may need an injection of hydrocortisone and immediate medical attention to prevent a life-threatening adrenal crisis [4][6]. You should receive proper training and a kit, rather than assuming you should self-treat without professional guidance.
  • Medical Alerts: It is highly recommended that patients wear a medical alert bracelet or carry a card stating they are on long-term steroid therapy, which can provide critical information to emergency responders [5].

Protecting the Heart, Eyes, and Brain

Because high blood pressure can impact the body’s smallest and largest blood vessels, regular “baseline” checks are used to monitor for early changes:

  • The Heart: An echocardiogram (an ultrasound of the heart) is used to check for left ventricular hypertrophy (heart thickening) [2]. While there is no universal schedule, these are often done at diagnosis and then periodically as determined by your specialist [2].
  • The Eyes: Regular eye exams help ensure the high blood pressure is not causing retinopathy (damage to the back of the eye) [2][7].
  • The Brain: FH-I is linked to a higher risk of intracranial aneurysms (weak spots in brain arteries) and early stroke [8][9]. Most experts suggest a shared, individualized discussion about “baseline” brain imaging—such as an MRA or CTA—especially if there is a family history of early strokes or aneurysms [10][8]. There is no universally accepted schedule. Note that CTA involves radiation and iodinated contrast, whereas MRA may involve sedation or contrast in children.

Monitoring Growth and Bone Health

For children and teenagers, the primary concern with long-term steroid use is its effect on physical development.

  • Growth Tracking: Your doctor will precisely track your child’s height velocity (how fast they are growing) and weight at every visit [11]. If growth slows down unexpectedly, it may be a sign that the steroid dose is too high [12].
  • Bone Density: Steroids can affect bone strength over time [13]. In some cases, a DXA scan (a specialized X-ray) may be used to monitor bone density, particularly if a child has a history of fractures [14]. Protective measures, such as Vitamin D and calcium intake, should be assessed and guided by your clinician rather than self-prescribed [15].

Your Role in Monitoring

Between doctor visits, your “home data” is the most valuable tool for your care team.

  • Home Blood Pressure Log: Keeping a consistent record of blood pressure at different times of the day helps your doctor adjust medications precisely [16][10]. Use a validated upper-arm cuff of the correct size. Take readings while seated and rested, and your doctor may sometimes order ambulatory blood pressure monitoring for a 24-hour view.
  • Routine Lab Assessment: Routine assessments of electrolytes (potassium, sodium), creatinine/eGFR, and urine protein directly affect treatment safety and should be ordered by your clinician.
  • Watch for “Red Flags”: Be aware of sudden, severe headaches or neurological changes, as previously discussed in the risks section, and report them to your medical team immediately [9][2].

By staying consistent with monitoring and medication, most families find they can successfully manage FH-I and prevent long-term complications [10][16].

Common questions in this guide

What should a sick-day plan cover for FH-I?
A written plan should explain when fever, severe infection, injury, or surgery requires a temporary increase in steroid medicine. It should give exact dose and timing instructions from the treating clinician; never taper or stop long-term steroids without medical advice.
What should I do if I cannot keep my steroid medicine down?
Vomiting can prevent oral medicine from being absorbed and may require an emergency hydrocortisone injection and immediate medical attention. Families should receive training and an emergency kit from their care team rather than creating their own dosing plan.
How is long-term FH-I treatment monitored?
Use a validated upper-arm cuff to record blood pressure while seated and rested, following the schedule given by your clinician. Your care team may also order blood tests for electrolytes and kidney function, urine protein testing, and other checks to guide safe treatment.
Does everyone with FH-I need heart, eye, or brain screening?
Specialists may use an echocardiogram and eye exams to look for effects of high blood pressure. Brain imaging with an MRA or CTA is individualized, especially when a family has early strokes or aneurysms, and there is no universally accepted schedule.
How are children monitored for steroid effects on growth and bones?
Clinicians track a child's height, growth rate, and weight because unexpectedly slow growth can signal that the steroid dose is too high. A DXA bone-density scan may be considered for children with fracture concerns, while vitamin D and calcium should be guided by the care team.
Why should someone with FH-I wear a medical alert bracelet?
Long-term steroid treatment can reduce the body's ability to make enough stress hormones during serious illness or injury. A medical alert bracelet or card tells emergency responders about the steroid therapy and the risk of adrenal insufficiency.

Get notified when new evidence is published on Familial hyperaldosteronism type I.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

    Mulatero P, Scholl UI, Fardella CE, et al.

    European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.

    PMID: 38571460
  2. 2

    Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.

    Tan ST, Boyle V, Elston MS

    Hypertension (Dallas, Tex. : 1979) 2023; (80(7)):1517-1525 doi:10.1161/HYPERTENSIONAHA.123.21054.

    PMID: 37170822
  3. 3

    Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations.

    Bowden SA, Connolly AM, Kinnett K, Zeitler PS

    Journal of neuromuscular diseases 2019; (6(1)):31-41 doi:10.3233/JND-180346.

    PMID: 30614808
  4. 4

    From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians.

    Murphy C, Nasomyont N, Tian C, et al.

    Neuromuscular disorders : NMD 2026; (62()):106411 doi:10.1016/j.nmd.2026.106411.

    PMID: 41894886
  5. 5

    Survey of Adrenal Insufficiency Management for Duchenne muscular dystrophy in Italy.

    Tornese G, Wong SC, Sbrocchi AM, et al.

    Endocrine 2026; (91(1)).

    PMID: 41920460
  6. 6

    The management of glucocorticoid deficiency: Current and future perspectives.

    Dineen R, Martin-Grace J, Thompson CJ, Sherlock M

    Clinica chimica acta; international journal of clinical chemistry 2020; (505()):148-159 doi:10.1016/j.cca.2020.03.006.

    PMID: 32145273
  7. 7

    Prevalence and Predictors of Bone and Ocular Complications in Children With Steroid-Sensitive Nephrotic Syndrome: A Cross-Sectional Study.

    Patel K, Kumar M, Singh SP, et al.

    Cureus 2026; (18(5)):e109153 doi:10.7759/cureus.109153.

    PMID: 42326092
  8. 8

    Intracranial aneurysm in a patient with glucocorticoid-remediable aldosteronism.

    Al Romhain B, Young AM, Battacharya JJ, Suttner N

    British journal of neurosurgery 2015; (29(5)):715-7 doi:10.3109/02688697.2015.1023775.

    PMID: 26021674
  9. 9

    A Case of Glucocorticoid Remediable Aldosteronism and Thoracoabdominal Aneurysms.

    Shahrrava A, Moinuddin S, Boddu P, Shah R

    Case reports in endocrinology 2016; (2016()):2017571 doi:10.1155/2016/2017571.

    PMID: 27366333
  10. 10

    Glucocorticoid Remediable Aldosteronism in a Family with a Strong History of Cerebral Aneurysms and Hypertension.

    Zeman J, Kamilaris C

    Prague medical report 2025; (126(3)):151-154 doi:10.14712/23362936.2025.23.

    PMID: 40966436
  11. 11

    Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions.

    Rutter MM, Crane JL, Babalola F, et al.

    Journal of neuromuscular diseases 2026; 22143602261486896 doi:10.1177/22143602261486896.

    PMID: 42857968
  12. 12

    Secondary Adrenal Insufficiency and Iatrogenic Cushing's Syndrome in a 13-Year-Old Male With Vogt-Koyanagi-Harada Disease: A Case Report.

    Paparella R, Bernabei I, Bei A, et al.

    Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2026; (40(3)):e125-e130 doi:10.1016/j.pedhc.2025.09.013.

    PMID: 41128702
  13. 13

    Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

    Ward LM, Hadjiyannakis S, McMillan HJ, et al.

    Pediatrics 2018; (142(Suppl 2)):S34-S42 doi:10.1542/peds.2018-0333E.

    PMID: 30275247
  14. 14

    Bone health in childhood and adolescence: an overview on dual-energy X-ray absorptiometry scanning, fracture surveillance and bisphosphonate therapy for low-middle-income countries.

    Madhuchani D, Seneviratne SN, Ward LM

    Frontiers in endocrinology 2023; (14()):1082413 doi:10.3389/fendo.2023.1082413.

    PMID: 37139332
  15. 15

    Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.

    Singh DN, Krishnamurthy S, Kamalanathan SK, et al.

    Paediatrics and international child health 2018; (38(4)):251-260 doi:10.1080/20469047.2018.1505589.

    PMID: 30092157
  16. 16

    Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.

    Izzo JL, Hong M, Hussain T, Osmond PJ

    Journal of clinical hypertension (Greenwich, Conn.) 2019; (21(8)):1183-1190 doi:10.1111/jch.13597.

    PMID: 31347775

This page is for informational purposes only and does not constitute medical advice. Your endocrinology team should set your medication, sick-day, emergency, and surveillance plans for familial hyperaldosteronism type I.